R2/BR/OR2
PreclinicalSmall molecule
R2/BR/OR2 is one of 16 small molecule programs targeting Marginal Zone B-Cell Lymphoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Marginal Zone B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Aliqopa
BayerApproved
Calquence
AstraZenecaApproved
Ukoniq
TTG Therapeutics, Inc.
Approved
Imbruvica
PPharmacyclics LLC.
Approved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Brukinsa
BBeOne Medicines
Approved
Treanda
AAzurity Pharmaceuticals
Approved
Rituxan
RochePhase 3
Gazyva
RochePhase 3
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for R2/BR/OR2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHenan Cancer Hospital